The goal of this research has been to evaluate the role of fibrin deposition and turnover in the biology of tumor growth, particularly with reference to tumor stroma formation. In the past year we have completed initial studies concerning the quantitation of fibrinogen influx and fibrin deposition and turnover in two well-characterized guinea pig carcinomas, line 1 and line 10 bile duct tumors. Earlier immunofluorescence studies revealed fibrin deposits in both tumors (line 1 much greater than line 10). In accord with these data, trace-labeled guinea pig fibrinogen (GPF) accumulated in both tumors in amounts that matched or exceeded plasma fibrinogen levels. However, line 1 tumor GPF content was four times that of line 10 tumors and 11 to 33 times that of normal subcutaneous tissue. The great bulk of accumulated GPF was in the form of cross linked (transglutaminated) fibrin. Because initial influx of fibrinogen into tumors and clotting were identical for both tumors, the large differences in GPF accumulation (line 1 greater than line 10) apparently reflect differences in fibrinolysis. Other studies have been concerned with the nature and importance of tumor-associated procoagulants to tumor fibrin deposition. Several tumor procoagulant activities have been identified in both the intrinsic and extrinsic coagulation pathways, as well as provision of a surface for prothrombinase generation, the penultimate step in the common coagulation pathway and one essential for clotting to proceed to completion. However, our studies in the past year have shown that tumor-associated procoagulants may be very much less important than had been thought earlier. We found that increased microvascular permeability alone is sufficient to induce equivalant extravascular coagulation in several normal tissues. The results indicate that saturating levels of procoagulant are present even in normal tissues in association with normal connective tissue cells. Therefore, the level of microvascular permeability becomes the rate limiting step in extravascular coagulation for solid tumors and also for a broad spectrum of inflammatory reactions. (A)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA028471-07
Application #
3168150
Study Section
Pathology B Study Section (PTHB)
Project Start
1980-02-01
Project End
1988-01-31
Budget Start
1986-02-01
Budget End
1987-01-31
Support Year
7
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Lin, K; Nagy, J A; Xu, H et al. (1994) Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Cancer Res 54:2269-77
Nagy, J A; Herzberg, K T; Dvorak, J M et al. (1993) Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 53:2631-43
Brown, L F; Dubin, D; Lavigne, L et al. (1993) Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. Am J Pathol 142:793-801
Sioussat, T M; Dvorak, H F; Brock, T A et al. (1993) Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch Biochem Biophys 301:15-20
Brown, L F; Lanir, N; McDonagh, J et al. (1993) Fibroblast migration in fibrin gel matrices. Am J Pathol 142:273-83
Dvorak, H F; Nagy, J A; Berse, B et al. (1992) Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci 667:101-11
Berse, B; Brown, L F; Van de Water, L et al. (1992) Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211-20
Brown, L F; Yeo, K T; Berse, B et al. (1992) Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 176:1375-9
Nagy, J A (1992) Lymphatic and nonlymphatic pathways of peritoneal absorption in mice: physiology versus pathology. Blood Purif 10:148-62
Shockley, T R; Lin, K; Nagy, J A et al. (1992) Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Cancer Res 52:367-76

Showing the most recent 10 out of 36 publications